PepGen Inc. — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 74/100
What the filing says
PepGen Inc. completed pricing of a public offering on November 11, 2026, selling 25,000,000 shares of common stock at $5.00 per share, generating $125 million in gross proceeds (approximately $117.5 million net after underwriting discounts of $0.30/share = 6%). Underwriters Leerink Partners, Stifel, and Guggenheim Securities received a 30-day option to purchase an additional 3,750,000 shares at the same price. Proceeds will fund clinical development of PGN-EDODM1 and general corporate purposes.
Why this rating
Massive capital raise (7.4x market cap) dramatically extends runway and validates biotech pipeline; transformational for ~$16.9M company despite typical biotech risk profile.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-6.7% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $5.08 ▲ 3.48% | at our read · unknown $4.91 | +10 min · unknown $4.61 ▼ 6.09% | +30 min · unknown $4.50 ▼ 8.23% | +1 hr · unknown $4.63 ▼ 5.70% | +4 hrs · unknown $4.55 ▼ 7.27% |
The stock had already moved -3.37% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.